Conservatives claim that too many NHS patients in England are being denied the use of new cancer drugs.
Andrew Lansley, the Shadow health secretary, stated that doctors should be given a larger role in making the decision over which drugs a patient should be prescribed.
As a result, the Conservative party is calling for manufacturers to reduce prices on drugs so that better deals will be available to patients. However, the medicine advisory body of the Government also recommended that the pricing is aimed at drugs that have clinical evidence behind them showing which patients will most likely benefit from their usage.
In a response, the Department of Health stated that the analysis provided by the Conservatives was misleading and selective.
A spokesman for the department stated that cancer is hard to beat and frightening to have so it is important that a complete approach is taken and not a selective approach when presenting the facts.
The Tories added that they would like to see a shift in the way that decisions are made within the medical community into doctors’ hands and out of NHS cost factors.
Lansley said that the country has reached a point where people known that there are certain new medicines that can improve a cancer prognosis and treatment plan and those drugs need to be more widely available through the NHS.
However, Sir Andrew Dillon of the National Institute of Health and Clinical Evidence, state that it would be wrong to provide these drugs to those where the benefit is still a question.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
